of quality of life with VCF patients after balloon kyphoplasty (BKP) was confirmed in a randomised controlled trial (Fracture REduction Evaluation (FREE) trial). Objective of this study was to examine a cost-effectiveness of BKP in comparison with conservative medical management (CMM) for VCF in patients with osteoporosis in Japan.
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Hiligsmann M, Rabenda V, Bruyère O, Reginster JY University of Liège, Liège, Belgium OBJECTIVES: Poor compliance and failure to persist with osteoporosis medications are common, but the clinical and economic consequences have not been well described. This study aims to estimate the clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients and to examine the scope for adherence-enhancing interventions. METHODS: A validated Markov microsimulation model estimated costs and outcomes (i.e. the number of fractures and the quality-adjusted life-year (QALY)) for three adherence scenarios: no treatment, realworld adherence and full adherence over three years. Simulated patients matched the populations where osteoporosis medications are reimbursed. The real-world adherence scenario employed adherence data from a published Belgian observational study and adherence was divided into persistence and compliance. The incremental cost per QALY gained was estimated comparing the three adherence scenarios. We also examined the clinical and economic implications of adherence-enhancing interventions assuming that adherence failure would be reduced by 10%, 20% or 30%. RESULTS: The estimated number of fractures prevented and the lifetime QALY gained in the real-world adherence scenario represents only 42.0% and 41.9% to that obtained under full adherence scenario, respectively. The cost per QALY gained of real-world adherence versus no treatment was estimated at a11,175, and full adherence was found to be cost-saving compared to real-world adherence. An intervention that decreases adherence failure by 20% was associated with a 28% increase in the number of fractures prevented and the costs per QALY gained compared to real-world adherence were respectively a29,350 and a46,275 if the intervention costs a100 and a150 per year. CONCLUSIONS: This study suggests that more than half of the potential benefits from oral bisphosphonates in patients with osteoporosis are lost due to poor compliance and failure to persist. Depending on its cost, interventions that improve adherence to therapy have the potential to be an attractive use of resources.
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COST-UTILITY OF EXERCISE THERAPY IN ADOLESCENTS AND YOUNG ADULTS SUFFERING FROM THE PATELLOFEMORAL PAIN SYNDROME
Tan S, van Linschoten R, van Middelkoop M, Koes B, Bierma-Zeinstra S, Koopmanschap M Erasmus MC, Rotterdam, The Netherlands OBJECTIVES: Because little is known about the cost effectiveness of exercise therapy, general practitioners lack the knowledge to apply the most cost effective treatment to patients with the patellofemoral pain syndrome (PFPS). Therefore, we aimed to determine the cost effectiveness of exercise therapy (intervention group) compared to 'usual care' (control group) in adolescents and young adults dealing with PFPS in primary care. METHODS: This multicenter prospective cost-utility analysis was conducted at 38 general practices and 3 sport medical advice centers in The Netherlands for 2007. A total of 131 patients between 14 and 40 years of age presenting with symptoms of PFPS and no history of previous active treatment were recruited. Direct medical and productivity costs were included for the follow up duration of one year. RESULTS: The annual direct medical costs per patient were significantly higher for the intervention group (a434) compared to the control group (a299), mainly caused by additional physiotherapy visits. Productivity costs amounted to a577 (SD2384) and a867 (SD2192) for the two groups respectively, resulting in annual societal costs per patient which were significantly lower in the intervention group (a 1,011 versus a1.166). Productivity costs due to reduced efficiency at paid work were responsible for 47% of the total costs in the intervention and 56% and in the control group. Patients in the intervention group experienced a slightly, but not significantly, higher quality of life (0.8722 versus 0.8617). CONCLUSIONS: When only direct medical costs were included, average costs per quality adjusted life year (QALY) were a12,754. However, with a societal average cost effectiveness ratio of -a14,738 per QALY, exercise therapy appears to be cost effective as compared to 'usual care'. The intervention was dominant in 52% of the cases (positive health effects and cost savings) and inferior in 14%.
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SHORT-TERM DISABILITY ASSOCIATED WITH HIP, NON-VERTEBRAL, AND VERTEBRAL FRACTURES IN THE UNITED STATES
Chung H 1 , Jhaveri M 2 , Skrepnek GH 3 1 Rutgers University, Piscataway, NJ, USA, 2 sanofi-aventis USA, Bridgewater, NJ, USA, 3 University of Arizona, Tucson, AZ, USA OBJECTIVES: Herniated discs (HDs) and depression place a significant burden on employers. Although less prevalent, fractures may also have associated burden. The objective of this study was to evaluate the burden of fractures compared to HD and depression in terms of short-term disability (STD). METHODS: A descriptive retrospective analysis was conducted to assess STD associated with fractures (hip, nonvertebral composite, vertebral). Medstat/MarketScan's Health and Productivity Management data from 2003-2007 were used. All patients were 45-64 year-old employees, stratified by gender. Fracture-related STD was defined as STD absence 7 days prior to 14 days after the date of first diagnosis of fracture. Cases were matched with a control with HD and a control with depression by age, gender, occupation, region, insurance type, and years of STD eligibility. RESULTS: HD and depression incidence was 30 and 55 per 1000 patient-years, respectively. Fracture incidence ranged from 0.6 cases for hip to 7 cases for nonvertebral fractures per 1,000 patientyears. However, a higher proportion of fracture patients had an STD absence compared to HD and depression controls. The proportion of events with an STD absence in women was 16.4% vs. 5.1%, 16.5% vs. 3.5%, and 11.8% vs. 5.4% for hip, nonvertebral, and vertebral fractures vs. depression, respectively. For men, the rates were 30.6% vs. 5.1%, 23.6% vs. 5.9%, and 23.7% vs. 6.7%. Comparison to HD controls yielded similar results. All p-values were 0.01. Among fracture patients, the mean days of STD absence (MDA) ranged from 93 (nonvertebral) to 148 (hip). The MDA was significantly higher (p 0.05) in women for vertebral (vs. HD controls) and in men for hip (vs. both controls), vertebral (vs. depression controls), and non-vertebral fractures (vs. depression controls). CONCLUSIONS: Although fracture incidence is lower than HDs or depression, fractures produce significantly higher STD burden per event in 45-64 year-old employees. To determine indirect costs of RA and investigate factors potentially associated with higher indirect costs. METHODS: A mail survey was carried out among working age Rheumatoid Arthritis (RA) patients members of one RA patients' association in France. Information on demographics, disease parameters, past and on-going treatments and employment status was collected. In addition, two validated instruments, Health Assessment Questionnaire (HAQ) and the EuroQoL-5 Dimension were considered. Annual indirect costs including sick leaves and RA-early retirement were valued from the French Health Insurance perspective. Two multiple logistic regression models were run to explain respectively the probability of having positive
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